ClinicalTrials.gg

Irritable Bowel Syndrome clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,120 studies for Irritable Bowel Syndrome across more than 10 countries. 211 are recruiting or about to start. 850 of them are mainly about Irritable Bowel Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18.

ClinicalTrials.gov finds 1,192 studies for Irritable Bowel Syndrome. How that becomes 1,120 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Irritable Bowel Syndrome, and those it files under no condition that list Irritable Bowel Syndromethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 1,192Found by its condition search · See all 1,192 hereIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −23List Irritable Bowel Syndrome as a condition, but the registry did not file them under itMost often written as “Constipation-predominant Irritable Bowel Syndrome” (7), “Irritable Bowel Syndrome With Diarrhea” (4), and “Irritable Bowel Syndrome With Constipation” (4). The registry filed them under other conditions only, most often Constipation (8) and Diarrhea (7).
  3. −49Match it another way44 name it in the title and 5 by a synonym or other text the search reads.
  4. 1,120The count on this page117 of them list Irritable Bowel Syndrome in their own words; the registry filed them under no condition.

Status

Completed
669
Status unknown
132
Recruiting
130
Not yet recruiting
67
Terminated
60
Withdrawn
22

Phase

Phase 2
168
Phase 3
98
Phase 4
72
Phase 1
39
Early Phase 1
6

Where

United States
344
China
74
Italy
68
United Kingdom
66
Sweden
59
Canada
55

Who develops what

Add Irritable Bowel Syndrome to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 5 programs from 5 companies, 4 with this as their studies’ main aim; 1 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Eli Lilly, GlaxoSmithKline and Valenta Pharm JSC here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 5 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 9 Mar 2027 est.camlipixant · GlaxoSmithKline · Phase 2 main aimNCT07519395 A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M) — primary endpoint: Change from Baseline in Weekly Abdominal pain intensity (API) over Weeks 7 to 12 · 420 enrolled
  • Jul 2027 est.brenipatide · Eli Lilly and Company · Phase 2 main aimNCT07545772 A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) — primary endpoint: Percentage of Participants with a Weekly Composite Clinical Response for at Least 50 Percent (%) of Weeks · 342 enrolled
  • 31 Aug 2027 est.Huanghou Zhixie Diwan group · Lei Yunshang Group · Phase 2 named, not the main aimNCT07721012 Huanghou Zhixie Diwan in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) — primary endpoint: Effective rate of IBS-D (weekly response) · 120 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Irritable Bowel Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Serotonin receptor agonists 1 open · SSRIs 1 open · 5-HT3 antagonists 10 · Antiemetics 6 · SNRIs 4

Coming up

63studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 130 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 85 (65%) stop at 75 or younger. 19 (15%) take children under 18. 4 (3%) are for women only and 1 (1%) for men only; 29 (22%) take healthy volunteers.

Recruiting studies that take each age, of 130
AgeWomenMen
1012 (9%)12 (9%)
18113 (87%)111 (85%)
30113 (87%)111 (85%)
40114 (88%)111 (85%)
50111 (85%)109 (84%)
6599 (76%)97 (75%)
7559 (45%)59 (45%)
8538 (29%)38 (29%)

Across all 1,120 studies, recruiting or not: 65% stop at 75 or younger and 42% at 65; 12% take children; 7% are for women only and <1% for men only; 25% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Irritable Bowel Syndrome studies take

Of 42 phase 2 interventional studies under Irritable Bowel Syndrome, half reached primary completion within 21 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 221 mo14–39 · 42 studies19 mo12–23 · 24 studies—
Phase 330 mo19–55 · 23 studies——
Phase 422 mo17–29 · 24 studies——
Interventional, no phase19 mo9–38 · 360 studies13 mo7–28 · 52 studies21 mo9–40 · 308 studies
Observational42 mo21–109 · 66 studies—67 mo28–193 · 52 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Stopped1

Newly registered14

Show 9 more

Studies

Recruiting first, then most recently updated. Showing 50 of 1,120. Browse all 1,120 → or search them.